Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Revealing oxidative stress-related genes in osteoporosis and advanced structural biological study for novel natural material discovery regarding MAPKAPK2

Autor: Yingjing Zhao, Weihang Li, Kuo Zhang, Meng Xu, Yujia Zou, Xiaotong Qiu, Tianxing Lu, Bo Gao

Publikováno v: Frontiers in Endocrinology, Vol 13 (2022)

ObjectivesThis study aimed to find novel oxidative stress (OS)-related biomarkers of osteoporosis (OP), together with targeting the macromolecule Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2) protein to further discover poten

Externí odkaz: https://doaj.org/article/b79f6d142bd64e1bb5307b7fc94d3710

Author Correction: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.

Autor: Herranz N; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Gallage S; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Metabolic Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Mellone M; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK., Wuestefeld T; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany.; Stem Cell & Regenerative Biology, Genome Institute of Singapore, Singapore, Singapore., Klotz S; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany., Hanley CJ; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK., Raguz S; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Acosta JC; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Innes AJ; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Banito A; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Georgilis A; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Montoya A; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Wolter K; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany., Dharmalingam G; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Faull P; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Carroll T; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Martínez-Barbera JP; Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London, UK., Cutillas P; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK., Reisinger F; Institute for Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany., Heikenwalder M; Institute for Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany.; Division of Chronic Inflammation and Cancer, German Cancer Research (DKFZ), Heidelberg, Germany., Miller RA; Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, Michigan, USA., Withers D; Metabolic Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Zender L; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany., Thomas GJ; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK., Gil J; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK. jesus.gil@csc.mrc.ac.uk.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK. jesus.gil@csc.mrc.ac.uk.

Publikováno v: Nature cell biology [Nat Cell Biol] 2024 Jun; Vol. 26 (6), pp. 1019.

Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium.

Autor: Manuel Sánchez-Maldonado, Jose^1,2,3 josemanuel.sanchez@genyo.es, Moñiz-Díez, Ana^1,2,3 ana.moniz@genyo.es, Horst, Rob ter⁴ RterHorst@cemm.oeaw.ac.at, Campa, Daniele⁵ daniele.campa@unipi.it, José Cabrera-Serrano, Antonio¹ antoniocabreraserrano@gmail.com, Martínez-Bueno, Manuel⁶ manuel.martinez@genyo.es, del Pilar Garrido-Collado, María^2,3 mariap.garrido.sspa@juntadeandalucia.es, Hernández-Mohedo, Francisca^2,3 paquihernandez@yahoo.es, Fernández-Puerta, Laura^2,3 lfernandez@fibaosalud.com, Ángel López-Nevot, Miguel⁷ mavenot@ugr.es, Cunha, Cristina^8,9 cristinacunha@med.uminho.pt, Antonio González-Sierra, Pedro^2,3 pedroa.gonzalez.sspa@juntadeandalucia.es, Springer, Jan¹⁰ bkr@goldmail.de, Lackner, Michaela¹¹ Michaela.lackner@i-med.ac.at, Alcazar-Fuoli, Laura¹² lalcazar@isciii.es, Fianchi, Luana¹³ luana.fianchi@policlinicogemelli.it, María Aguado, José¹⁴ jaguadog1@gmail.com, Pagano, Livio¹³ livio.pagano@policlinicogemelli.it, López-Fernández, Elisa^2,3 eliku77@hotmail.com, Clavero, Esther^2,3 eclaverosa@hotmail.com

Publikováno v: Journal of Fungi. Jan2021, Vol. 7 Issue 1, p1-17. 17p.

MAPKAPK2 plays a crucial role in the progression of head and neck squamous cell carcinoma by regulating transcript stability

Autor: Sourabh Soni, Munish Kumar Saroch, Bal Chander, Narendra Vijay Tirpude, Yogendra S. Padwad

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-13 (2019)

Abstract Background Head and neck squamous-cell carcinoma (HNSCC) ranks sixth among cancers worldwide. Though several molecular mechanisms of tumor initiation and progression of HNSCC are known, others remain unclear. Significance of p38/MAPKAPK2 (Mi

Externí odkaz: https://doaj.org/article/0509179cbc954eff879a0ca9fe280d46